Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Novavax has given back most of Monday's dramatic gain, and the short position that was briefly squeezed is quietly reasserting itself as the week closes.
The stock ended Wednesday at $11.22, down from the $12.56 close that followed Monday's plague-scare rally. The one-week gain is now 3.8%, a fraction of what it was at Monday's peak. That reversal matters because the prior note documented exactly why a 20% up-day is so painful on a stock with nearly 29% of the free float short: for a squeeze to hold, the catalyst has to be durable. Reports of suspected pneumonic plague cases in Russia were not. Short interest, which dipped modestly through mid-September from a peak above 48 million shares in the first half of the month, has crept back up to 46.9 million shares, equating to 28.8% of the free float. The week-on-week change is essentially flat, down 0.2%, but the one-month trend is higher by 4.1%. Bears who covered into Monday's spike appear to have reloaded.
The lending market tells a notably different story from two weeks ago. Availability has loosened sharply. At the end of September, the ratio of shares still available to borrow relative to shares already borrowed had fallen as low as 21%, meaning fewer than one share was available for every four already lent. By Wednesday it had recovered to 60%, the most available borrow space in more than a month. Cost to borrow has also eased, dropping 16% on the week to 0.71%, well below the readings above 1% that prevailed through much of September. The 52-week low for availability was 0.15%, so conditions are nowhere near a genuine squeeze. The borrow market has effectively normalised after Monday's noise. Options positioning reinforces this: the put/call ratio came in at 0.54, running about 1.5 standard deviations below its 20-day mean of 0.58. That is a call-skewed setup, consistent with traders positioning for upside, but it is a modest lean rather than an extreme. The 52-week low on the PCR is 0.38, so there is room for calls to become significantly more dominant.
The Street's view on Novavax is split and the most recent analyst data is dated, which limits conclusions. The mean price target on file is around $14, implying roughly 25% upside from current levels, but the freshest move in the record is from BTIG in June, reiterating a Buy with a $19 target. JP Morgan holds an Underweight with a $6 target. The bull case, updated as recently as October 2, centres on Matrix-M as a differentiated adjuvant with broad partnership potential across infectious disease and oncology, alongside Nuvaxovid royalties projected in the high-teens to low-20s range. The bear case is more pressing: physician surveys point to an 11% drop in vaccinated US adults this season, IQVIA prescription data showed a 26% decline in COVID-19 vaccine scripts through late 2025, and FDA/CDC guideline changes in 2025 have narrowed the eligible population. The ORTEX short score is 78.7, easing slightly from above 80 earlier in the week, but still ranking in the 97th percentile of the universe. The EPS momentum factor at 30 days sits at the 9th percentile, reflecting recent estimate cuts.
Ownership is where one genuinely newsworthy element sits. Himanshu Shah of Shah Capital Management filed a Schedule 13D in October 2025 and has since amended it four times, most recently in May 2026. His stake sits at 9.03% of the class, as last disclosed, a slight trim from 9.11% previously. A Schedule 13D signals active rather than passive intent, and Shah's repeated amendments indicate continued engagement with the position. BlackRock and State Street have each been adding shares, with State Street reporting a large increase to 7.1% on its last 13G. Sanofi, which holds 4.2% as a strategic partner, has held its position flat. Stakes are as-last-disclosed and a holder dropping below 5% may not file again, so these should be treated as lagging indicators of ownership rather than current positions.
Retail attention, measured by Wikipedia page views, registered a z-score of 2.9 against Novavax's own 90-day history as of October 6. That is a measure of attention, not a fundamental signal, and as the prior note made clear, it reflects the plague-news spike rather than any change in the company's business trajectory. Earnings are next due November 9, 32 days away. The prior print, on August 6, produced a 3.2% one-day gain and a 5.7% five-day gain. Whether the crowded short position amplifies or absorbs that move depends on whether cost to borrow and availability stay at current relaxed levels, or whether a fresh catalyst sends shorts scrambling again before the release date.
See the live data behind this article on ORTEX.
Open NVAX on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
